Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POD1UM-303/InterAACT 2 in first-line advanced anal squamous cell carcinoma
2020-000826-24Phase 3Active
- Sponsor
- Incyte
- Start
- Jul 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in anal squamous cell carcinoma (SCCA) comparing Retifanlimab + carboplatin + paclitaxel with Placebo + carboplatin + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Jul 2020; status: active.
02
Drugs
retifanlimabcarboplatinpaclitaxel
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on 2020-000826-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000826-24.